This company listing is no longer active
Morphic Holding Future Growth
Future criteria checks 2/6
Morphic Holding's earnings are forecast to decline at 6.4% per annum while its annual revenue is expected to grow at 81.5% per year. EPS is expected to decline by 0.6% per annum. Return on equity is forecast to be -87.8% in 3 years.
Key information
-6.4%
Earnings growth rate
-0.6%
EPS growth rate
| Biotechs earnings growth | 36.2% |
| Revenue growth rate | 81.5% |
| Future return on equity | -87.8% |
| Analyst coverage | Good |
| Last updated | 07 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | -251 | -203 | -195 | 7 |
| 12/31/2025 | 1 | -232 | -191 | -179 | 9 |
| 12/31/2024 | 0 | -213 | -173 | -162 | 10 |
| 6/30/2024 | N/A | -180 | -138 | -136 | N/A |
| 3/31/2024 | N/A | -161 | -129 | -127 | N/A |
| 12/31/2023 | 1 | -152 | -114 | -112 | N/A |
| 9/30/2023 | 7 | -136 | -110 | -109 | N/A |
| 6/30/2023 | 9 | -130 | -106 | -104 | N/A |
| 3/31/2023 | 69 | -64 | -105 | -104 | N/A |
| 12/31/2022 | 71 | -59 | -101 | -101 | N/A |
| 9/30/2022 | 74 | -56 | -97 | -96 | N/A |
| 6/30/2022 | 75 | -51 | -97 | -96 | N/A |
| 3/31/2022 | 19 | -106 | -92 | -91 | N/A |
| 12/31/2021 | 20 | -96 | -84 | -83 | N/A |
| 9/30/2021 | 16 | -92 | -78 | -77 | N/A |
| 6/30/2021 | 39 | -61 | -49 | -49 | N/A |
| 3/31/2021 | 43 | -50 | -48 | -47 | N/A |
| 12/31/2020 | 45 | -45 | -47 | -46 | N/A |
| 9/30/2020 | 39 | -47 | -47 | -46 | N/A |
| 6/30/2020 | 19 | -61 | -65 | -63 | N/A |
| 3/31/2020 | 17 | -55 | -63 | -61 | N/A |
| 12/31/2019 | 17 | -43 | -44 | -42 | N/A |
| 9/30/2019 | 21 | -29 | 63 | 65 | N/A |
| 6/30/2019 | 15 | -27 | 72 | 73 | N/A |
| 3/31/2019 | 9 | -24 | 81 | 82 | N/A |
| 12/31/2018 | 3 | -24 | 76 | 76 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 31Y is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 31Y is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 31Y is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 31Y's revenue (81.5% per year) is forecast to grow faster than the German market (5.3% per year).
High Growth Revenue: 31Y's revenue (81.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 31Y is forecast to be unprofitable in 3 years.